ERBB2 and urinary bladder carcinoma: There is evidence that HER2 acts as an oncogenic driver in a subset of bladder carcinoma cases [9], which supports the hypothesis that its overexpression might worsen clinical behavior, but definitive conclusions can be made only after prospective validation studies.